Company biOasis Technologies Inc Toronto S.E.
Equities
BTI
CA09064N1033
Biotechnology & Medical Research
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Diagnosis and Treatment of Neurological Diseases and Disorders
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -99.07% |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -99.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Deborah Rathjen
CEO | Chief Executive Officer | - | 21/17/21 |
Dave Jenkins
DFI | Director of Finance/CFO | - | 01/21/01 |
Mei Mei Tian
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/01 |
Graeme Dick
IRC | Investor Relations Contact | - | 01/11/01 |
Christopher Lowe
SEC | Corporate Secretary | 56 | 03/17/03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Hemeon
BRD | Director/Board Member | 59 | - |
David Wurzer
BRD | Director/Board Member | 65 | 27/18/27 |
Deborah Rathjen
CEO | Chief Executive Officer | - | 21/17/21 |
Director/Board Member | 63 | 01/18/01 | |
John E. Curran
BRD | Director/Board Member | - | 27/18/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 79,414,015 | 77,784,778 ( 97.95 %) | 0 | 97.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |